Compare SEAT & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEAT | PMN |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.0M | 84.1M |
| IPO Year | 2021 | 2022 |
| Metric | SEAT | PMN |
|---|---|---|
| Price | $2.72 | $8.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $11.68 | ★ $42.90 |
| AVG Volume (30 Days) | ★ 71.4K | 23.8K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.74 | $0.29 |
| 52 Week High | $13.87 | $27.40 |
| Indicator | SEAT | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 25.52 | 36.84 |
| Support Level | N/A | $7.96 |
| Resistance Level | $7.68 | $15.15 |
| Average True Range (ATR) | 0.24 | 0.75 |
| MACD | 0.06 | 0.11 |
| Stochastic Oscillator | 0.00 | 25.96 |
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry, providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada, and Japan. It operates in two segments: Marketplace, which generates maximum revenue, and Resale. The Marketplace segment acts as an intermediary between ticket buyers, sellers, and partners, earning revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. The Resale segment acquires tickets to resell on secondary ticket marketplaces, including its own, and offers internal research and development support for Skybox.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.